XKDCT-023

N/A

Report date: 2025/01/26 17:20:57

Base Information

Drug NameXKDCT-023
Drug Alias NameAutologous Anti-CD19 CAR T-Cell Therapy (The Affiliated Hospital of Qingdao University)Anti-CD19 CAR T-Cell Therapy (The Affiliated Hospital of Qingdao University)XKDCT-023
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesThe Affiliated Hospital Of Qingdao University
China Registration ClassN/A

Develop Information

Active CompaniesThe Affiliated Hospital Of Qingdao University
Inactive CompaniesN/A
Active IndicationsLymphoma, Large B-Cell, Diffuse
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A